SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies other receptor tyrosine kinases (RT...

Descripción completa

Detalles Bibliográficos
Autores principales: Pudelko, Linda, Jaehrling, Frank, Reusch, Christof, Vitri, Sanziago, Stroh, Christopher, Linde, Nina, Sanderson, Michael P., Musch, Doreen, Lebrun, Catherine Jorand, Keil, Marina, Esdar, Christina, Blaukat, Andree, Rosell, Rafael, Schumacher, Karl Maria, Karachaliou, Niki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718487/
https://www.ncbi.nlm.nih.gov/pubmed/33305187
http://dx.doi.org/10.1016/j.isci.2020.101832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718487/
https://www.ncbi.nlm.nih.gov/pubmed/33305187
http://dx.doi.org/10.1016/j.isci.2020.101832

Ejemplares similares